Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Unfortunately for some shareholders, the Adaptimmune Therapeutics plc (NASDAQ:ADAP) share price has dived 32% in the last thirty days, prolonging recent pain. Looking back over the past twelve months the stock has been a solid performer regardless, with a gain of 23%.

Following the heavy fall in price, Adaptimmune Therapeutics may be sending very bullish signals at the moment with its price-to-sales (or "P/S") ratio of 1.1x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 11.5x and even P/S higher than 68x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.

View our latest analysis for Adaptimmune Therapeutics

How Adaptimmune Therapeutics Has Been Performing

With revenue growth that's exceedingly strong of late, Adaptimmune Therapeutics has been doing very well. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the P/S ratio. Those who are bullish on Adaptimmune Therapeutics will be hoping that this isn't the case, so that they can pick up the stock at a lower valuation.

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Adaptimmune Therapeutics' earnings, revenue and cash flow.

Is There Any Revenue Growth Forecasted For Adaptimmune Therapeutics?

In order to justify its P/S ratio, Adaptimmune Therapeutics would need to produce anemic growth that's substantially trailing the industry.

Taking a look back first, we see that the company grew revenue by an impressive 100% last year. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.

This is in contrast to the rest of the industry, which is expected to grow by 91% over the next year, materially lower than the company's recent medium-term annualised growth rates.

With this information, we find it odd that Adaptimmune Therapeutics is trading at a P/S lower than the industry. It looks like most investors are not convinced the company can maintain its recent growth rates.

What Does Adaptimmune Therapeutics' P/S Mean For Investors?

Shares in Adaptimmune Therapeutics have plummeted and its P/S has followed suit. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Our examination of Adaptimmune Therapeutics revealed its three-year revenue trends aren't boosting its P/S anywhere near as much as we would have predicted, given they look better than current industry expectations. When we see robust revenue growth that outpaces the industry, we presume that there are notable underlying risks to the company's future performance, which is exerting downward pressure on the P/S ratio. It appears many are indeed anticipating revenue instability, because the persistence of these recent medium-term conditions would normally provide a boost to the share price.

There are also other vital risk factors to consider and we've discovered 4 warning signs for Adaptimmune Therapeutics (1 is concerning!) that you should be aware of before investing here.

If these risks are making you reconsider your opinion on Adaptimmune Therapeutics, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.